Kane Biotech Announces Publication of revyve® Wound Gel Article in the International Wound Journal

Core Insights - Kane Biotech Inc. has published an article on its revyve Antimicrobial wound gel in the International Wound Journal, highlighting the gel's wound healing properties and antimicrobial activity [1][2] Group 1: Publication and Validation - The article titled "Wound Healing Property of a Novel Thermo-Reversible Wound Gel With Lasting Antimicrobial and Antibiofilm Activity" is authored by Dr. Jeyachchandran Visvalingam and includes contributions from the University of Miami [1] - The publication in a peer-reviewed journal underscores the scientific rigor of revyve technology and provides independent validation of the gel's safety and clinical potential [3] Group 2: Product Efficacy and Features - The revyve Antimicrobial Wound Gel demonstrates efficacy against a range of wound-related pathogens, achieving a 99.99% to 99.9999% reduction in bacterial counts within 30 minutes [7] - The gel exhibits sustained in vitro activity for up to 7 days, potentially reducing the frequency of dressing changes [7] - It is designed as a thermo-reversible gel that transitions from a liquid to a gel at body temperature, allowing for easy removal [7] Group 3: Company Overview - Kane Biotech is focused on developing novel wound care treatments that target biofilms, which contribute to antibiotic resistance and adverse clinical outcomes [4] - The revyve product line, including the Antimicrobial Wound Gel and Spray, has received U.S. FDA 510(k) clearance and Health Canada approval [4]